Compare PLUR & PLSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLUR | PLSM |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 14.4M |
| IPO Year | 2026 | 2025 |
| Metric | PLUR | PLSM |
|---|---|---|
| Price | $0.95 | $1.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.6K | ★ 37.2K |
| Earning Date | 11-11-2026 | 08-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,016,000.00 | N/A |
| Revenue This Year | $902.46 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $1.75 |
| 52 Week High | $4.87 | $12.97 |
| Indicator | PLUR | PLSM |
|---|---|---|
| Relative Strength Index (RSI) | 32.70 | 30.74 |
| Support Level | $0.90 | N/A |
| Resistance Level | $1.85 | $2.64 |
| Average True Range (ATR) | 0.09 | 0.21 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 27.43 | 15.12 |
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.